Latest Kaiser Health News Stories
A study ordered by the Food and Drug Administration failed to prove that Makena, the only drug approved to prevent premature birth, is effective. While a panel of experts has recommended withdrawing the drug’s approval, many doctors are wary.
The scientific use of tissue from aborted fetuses has frequently been a hot point of contention between anti-abortion forces and researchers. It heats up again as federal officials announced this week they were ending NIH research using the tissue.
Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post join KHN’s Julie Rovner to discuss the Trump administration’s efforts to curtail federally funded research using fetal tissue, the backlash from former Vice President Joe Biden’s support for the anti-abortion Hyde Amendment and how health policy intersects with both trade and immigration policy.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
President Donald Trump wants Congress to allot $500 million over 10 years for pediatric cancer research. While it’s welcomed by researchers and advocates, it’s not a lot of money.
The Michigan Democrat chaired the House Energy and Commerce Committee and his impact on health care was immense.
Health was a featured player in President Donald Trump’s 2019 State of the Union address. The president set goals to bring down prescription drug prices, end the HIV epidemic in the U.S. and cure childhood cancer, among other things. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Alice Ollstein of Politico join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN senior correspondent Phil Galewitz about the current “Bill of the Month” feature.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
KHN’s Mary Agnes Carey and Julie Rovner discuss some of the developments that shook up health news this week.
An NIH-funded network of hospitals uses advanced genetic science and nationwide collaboration to diagnose rare and sometimes undiscovered diseases.
Among the institutions that stand to lose most are those in California, especially the University of California and Stanford University.
In a paradox, researchers say testing for a vaccine will depend on the outbreak recurring this year.
Two prescription medications have been found to be successful in helping many patients with alcohol cravings. Yet they are rarely used and many patients don’t know they exist.
Some clinics on NIH’s website charge people to participate in testing of unproven treatments — and it can come as a surprise to unsuspecting patients.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, recently spoke with KHN’s Carmen Heredia Rodriguez about vaccine development and the ongoing fight in Congress over emergency funding.
Some say this trend is the future of biomedical research. But along with its potential, it also faces significant challenges.
A report from the National Academies of Sciences, Engineering and Medicine calls for the White House to lead a national strategy to promote and continue advances in trauma care.
It’s not clear yet if the full Senate or House will concur in the plan to cut funding for the State Health Insurance Assistance Program, which operates in all states and gives beneficiaries free advice on enrollment in drug and insurance plans, appealing coverage decisions and applying for financial subsidies.
Five states have already eliminated sales tax on feminine products, and New York City is also trying to make the products available for free in schools.